These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31292220)

  • 21. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
    Hollstein T; Vogt A; Grenkowitz T; Stojakovic T; März W; Laufs U; Bölükbasi B; Steinhagen-Thiessen E; Scharnagl H; Kassner U
    Vascul Pharmacol; 2019 May; 116():8-15. PubMed ID: 30910670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
    Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
    JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
    Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    J Atheroscler Thromb; 2022 Jan; 29(1):24-37. PubMed ID: 33342939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Artificial Platelets for Efficient siRNA Delivery to Clear "Bad Cholesterol".
    Zhang Y; Qin Y; Li H; Peng Q; Wang P; Yang L; Chen S; Li M; Fu J; Yu X; Zhang L
    ACS Appl Mater Interfaces; 2020 Jun; 12(25):28034-28046. PubMed ID: 32469502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
    Reyes-Soffer G; Pavlyha M; Ngai C; Thomas T; Holleran S; Ramakrishnan R; Karmally W; Nandakumar R; Fontanez N; Obunike J; Marcovina SM; Lichtenstein AH; Matthan NR; Matta J; Maroccia M; Becue F; Poitiers F; Swanson B; Cowan L; Sasiela WJ; Surks HK; Ginsberg HN
    Circulation; 2017 Jan; 135(4):352-362. PubMed ID: 27986651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PCSK9 Biology and Its Role in Atherothrombosis.
    Barale C; Melchionda E; Morotti A; Russo I
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects.
    Kwakernaak AJ; Lambert G; Muller Kobold AC; Dullaart RP
    Thyroid; 2013 Feb; 23(2):166-72. PubMed ID: 23106476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
    Colhoun HM; Leiter LA; Müller-Wieland D; Cariou B; Ray KK; Tinahones FJ; Domenger C; Letierce A; Israel M; Samuel R; Del Prato S
    Cardiovasc Diabetol; 2020 Feb; 19(1):14. PubMed ID: 32035487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies.
    Mahmood T; Minnier J; Ito MK; Li QH; Koren A; Kam IW; Fazio S; Shapiro MD
    Eur J Prev Cardiol; 2021 Jul; 28(8):816-822. PubMed ID: 34298554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor.
    Sun H; Samarghandi A; Zhang N; Yao Z; Xiong M; Teng BB
    Arterioscler Thromb Vasc Biol; 2012 Jul; 32(7):1585-95. PubMed ID: 22580899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.
    Koren MJ; Sabatine MS; Giugliano RP; Langslet G; Wiviott SD; Kassahun H; Ruzza A; Ma Y; Somaratne R; Raal FJ
    JAMA Cardiol; 2017 Jun; 2(6):598-607. PubMed ID: 28291870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial.
    Leiter LA; Teoh H; Kallend D; Wright RS; Landmesser U; Wijngaard PLJ; Kastelein JJP; Ray KK
    Diabetes Care; 2019 Jan; 42(1):173-176. PubMed ID: 30487231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9.
    Ason B; Tep S; Davis HR; Xu Y; Tetzloff G; Galinski B; Soriano F; Dubinina N; Zhu L; Stefanni A; Wong KK; Tadin-Strapps M; Bartz SR; Hubbard B; Ranalletta M; Sachs AB; Flanagan WM; Strack A; Kuklin NA
    J Lipid Res; 2011 Apr; 52(4):679-87. PubMed ID: 21262787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of long-term physical activity on PCSK9, high- and low-density lipoprotein cholesterol, and lipoprotein(a) levels: a prospective observational trial.
    Sponder M; Campean IA; Dalos D; Emich M; Fritzer-Szekeres M; Litschauer B; Bergler-Klein J; Graf S; Strametz-Juranek J
    Pol Arch Intern Med; 2017 Aug; 127(7-8):506-511. PubMed ID: 28607329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab.
    Shapiro MD; Minnier J; Tavori H; Kassahun H; Flower A; Somaratne R; Fazio S
    J Am Heart Assoc; 2019 Feb; 8(4):e010932. PubMed ID: 30755061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of lipoprotein apheresis on PCSK9 levels.
    Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
    Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.